Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
By the end of the study, around half of participants were on SGLT2 inhibitors
10.1038/cddis.2014.221 56 ZhangQ.LiuJ.DengM
:max_bytes(150000):strip_icc()/HEALTH-DWL-frame-final-zepbound-660e231e08ed4501aac307f06936227c.jpg)
This class of medications treats type 2 diabetes and obesity
Heres what we know and dont know: Most cases were described as mild and did not lead to stopping the drug Its not seen with semaglutide or tirzepatide it may be related to glucagon receptor activation, but this isnt confirmed The Phase 2 trial did note altered or enhanced skin sensation at lower rates, so it may not be entirely new just more apparent at scale It needs investigation across the remaining 7 Phase 3 trials reporting in 2026 Is it a dealbreaker
US$ 25.09
US$ 27.76
US$ 28.40
US$ 26.82
US$ 28.68
